Brookline, MA, United States of America

Qingsong Liu

This inventor holds 4 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Dana-Farber-Cancer Institute Inc., Whitehead Institute for Biomedical Research, Beth Israel Deaconess Medical Center, Inc.. Active years: 2013-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qingsong Liu. Retrieved from https://idiyas.com/inventor/qingsong-liu-4l772a84

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 100.0


Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 87(Granted Patents)


Location History:

  • Jamaica Plain, MA (US) (2013)
  • Brookline, MA (US) (2014 - 2018)

Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Qingsong Liu

Introduction

Qingsong Liu is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of biomedical research, particularly in the development of novel compounds for treating various diseases. With a total of 4 patents, his work has the potential to impact the treatment of both proliferative and infectious diseases.

Latest Patents

One of Liu's latest patents focuses on Bone marrow on X chromosome kinase (BMX) inhibitors and their uses. This invention provides novel compounds of Formula (I), along with pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The methods and kits involving these compounds aim to treat or prevent a wide range of diseases, including cancers, inflammatory diseases, and metabolic disorders such as type 2 diabetes. The treatment may downregulate the expression and inhibit the activity of kinases, particularly BMX, thereby suppressing tyrosine kinase signaling in subjects.

Another significant patent involves host-targeted inhibitors of dengue virus and other viruses. This invention presents novel antiviral compounds of Formulae (I)-(III). The compounds, along with their pharmaceutical compositions and kits, are designed for the prevention and treatment of infectious diseases caused by various viruses, including Dengue virus, Ebola virus, and others.

Career Highlights

Qingsong Liu has worked with prestigious institutions such as Dana-Farber Cancer Institute and the Whitehead Institute for Biomedical Research. His experience in these organizations has allowed him to contribute to groundbreaking research in the field of cancer and infectious diseases.

Collaborations

Liu has collaborated with notable colleagues, including Nathanael Schiander Gray and Jae Won Chang. These partnerships have further enhanced his research capabilities and broadened the impact of his inventions.

Conclusion

Qingsong Liu's innovative work in developing novel compounds for treating diseases showcases his dedication to advancing biomedical research. His contributions have the potential to significantly improve treatment options for various health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…